Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Breast Neoplasms 234Neoplasms 206Carcinoma, Non-Small-Cell Lung 100Colorectal Neoplasms 98Prostatic Neoplasms 93Lung Neoplasms 78Multiple Myeloma 53Melanoma 51Pancreatic Neoplasms 50Head and Neck Neoplasms 49Neoplasm Metastasis 47Leukemia, Myeloid, Acute 43Carcinoma, Hepatocellular 43Ovarian Neoplasms 39Brain Neoplasms 39Squamous Cell Carcinoma of Head and Neck 36Recurrence 35Glioblastoma 33Uterine Cervical Neoplasms 32Sarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Glioma 29Lymphoma, Non-Hodgkin 28Lymphoma 27Colonic Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Lymphoma, Follicular 25Esophageal Neoplasms 24Rectal Neoplasms 23

Interventions

pembrolizumab 1Pharmacogenomic Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solitary Fibrous Tumor, Pleural × 90 days × Clear all
NCT02399371 2026-05-08

Pembrolizumab in Treating Patients With Malignant Mesothelioma

University of Chicago

Phase 2 Completed
65 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡